Treating cancer by targeting telomeres and telomerase

Antioxidants

Volumn 6, Issue 1, 2017, Pages

  Ivancich, Marko ^a   Schrank, Zachary ^a   Wojdyla, Luke ^a   Leviskas, Brandon ^a   Kuckovic, Adijan ^a   Sanjali, Ankita ^a   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

DNA damage responses; G quadruplex; Guanine rich oligonucleotides (GROs); Shelterin complex; Telomerase; Telomere homolog oligonucleotides (T oligos)

Indexed keywords

EID: 85013987379     PISSN: None     EISSN: 20763921     Source Type: Journal    
DOI: 10.3390/antiox6010015     Document Type: Review

References (85)

1. Crees, Z.; Girard, J.; Rios, Z.; Botting, G.M.; Harrington, K.; Shearrow, C.; Wojdyla, L.; Stone, A.L.; Uppada, S.B.; Devito, J.T.; et al. Oligonucleotides and g-quadruplex stabilizers: Targeting telomeres and telomerase in cancer therapy. Curr. Pharm. Des. 2014, 20, 6422–6437. [CrossRef] [PubMed]
2. Ruden, M.; Puri, N. Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev. 2013, 39, 444–456. [CrossRef] [PubMed]
3. Thilagavathi, J.; Venkatesh, S.; Dada, R. Telomere length in reproduction. Andrologia 2013, 45, 289–304. [CrossRef] [PubMed]
4. Reig-Viader, R.; Garcia-Caldes, M.; Ruiz-Herrera, A. Telomere homeostasis in mammalian germ cells: A review. Chromosoma 2016, 125, 337–351. [CrossRef] [PubMed]
5. Antunes, D.M.; Kalmbach, K.H.; Wang, F.; Dracxler, R.C.; Seth-Smith, M.L.; Kramer, Y.; Buldo-Licciardi, J.; Kohlrausch, F.B.; Keefe, D.L. A single-cell assay for telomere DNA content shows increasing telomere length heterogeneity, as well as increasing mean telomere length in human spermatozoa with advancing age. J. Assist. Reprod. Genet. 2015, 32, 1685–1690. [CrossRef] [PubMed]
6. O’Sullivan, R.J.; Karlseder, J. Telomeres: Protecting chromosomes against genome instability. Nat. Rev. Mol. Cell Biol. 2010, 11, 171–181. [CrossRef] [PubMed]
7. De Lange, T. Protection of mammalian telomeres. Oncogene 2002, 21, 532–540. [CrossRef] [PubMed]
8. Dimitrova, N.; de Lange, T. Cell cycle-dependent role of MRN at dysfunctional telomeres: ATM signaling-dependent induction of nonhomologous end joining (NHEJ) in G1 and resection-mediated inhibition of NHEJ in G2. Mol. Cell. Biol. 2009, 29, 5552–5563. [CrossRef] [PubMed]
9. Ribes-Zamora, A.; Indiviglio, S.M.; Mihalek, I.; Williams, C.L.; Bertuch, A.A. TRF2 interaction with Ku heterotetramerization interface gives insight into c-NHEJ prevention at human telomeres. Cell Rep. 2013, 5, 194–206. [CrossRef] [PubMed]
10. Jafri, M.A.; Ansari, S.A.; Alqahtani, M.H.; Shay, J.W. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016, 8, 69. [CrossRef] [PubMed]
11. Dunham, M.A.; Neumann, A.A.; Fasching, C.L.; Reddel, R.R. Telomere maintenance by recombination in human cells. Nat. Genet. 2000, 26, 447–450. [PubMed]
12. Luke-Glaser, S.; Poschke, H.; Luke, B. Getting in (and out of) the loop: Regulating higher order telomere structures. Front. Oncol. 2012, 2, 180. [CrossRef] [PubMed]
13. Xu, Y.; Goldkorn, A. Telomere and telomerase therapeutics in cancer. Genes 2016, 7, 22. [CrossRef] [PubMed]
14. Zurek, M.; Altschmied, J.; Kohlgruber, S.; Ale-Agha, N.; Haendeler, J. Role of telomerase in the cardiovascular system. Genes 2016, 7, 29. [CrossRef] [PubMed]
15. Pech, M.F.; Garbuzov, A.; Hasegawa, K.; Sukhwani, M.; Zhang, R.J.; Benayoun, B.A.; Brockman, S.A.; Lin, S.; Brunet, A.; Orwig, K.E.; et al. High telomerase is a hallmark of undifferentiated spermatogonia and is required for maintenance of male germline stem cells. Genes Dev. 2015, 29, 2420–2434. [CrossRef] [PubMed]
16. Collins, K.; Mitchell, J.R. Telomerase in the human organism. Oncogene 2002, 21, 564–579. [CrossRef] [PubMed]
17. Shay, J.W.; Wright, W.E. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett. 2010, 584, 3819–3825. [CrossRef] [PubMed]
18. Shigeishi, H.; Sugiyama, M.; Tahara, H.; Ono, S.; Kumar Bhawal, U.; Okura, M.; Kogo, M.; Shinohara, M.; Shindoh, M.; Shintani, S.; et al. Increased telomerase activity and htert expression in human salivary gland carcinomas. Oncol. Lett. 2011, 2, 845–850. [CrossRef] [PubMed]
19. Poncet, D.; Belleville, A.; t’kint de Roodenbeke, C.; Roborel de Climens, A.; Ben Simon, E.; Merle-Beral, H.; Callet-Bauchu, E.; Salles, G.; Sabatier, L.; Delic, J.; et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 2008, 111, 2388–2391. [CrossRef] [PubMed]
20. Cesare, A.J.; Reddel, R.R. Alternative lengthening of telomeres: Models, mechanisms and implications. Nat. Rev. Genet. 2010, 11, 319–330. [CrossRef] [PubMed]
21. Chiappori, A.A.; Kolevska, T.; Spigel, D.R.; Hager, S.; Rarick, M.; Gadgeel, S.; Blais, N.; Von Pawel, J.; Hart, L.; Reck, M.; et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015, 26, 354–362. [CrossRef] [PubMed]
22. Asai, A.; Oshima, Y.; Yamamoto, Y.; Uochi, T.A.; Kusaka, H.; Akinaga, S.; Yamashita, Y.; Pongracz, K.; Pruzan, R.; Wunder, E.; et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003, 63, 3931–3939. [PubMed]
23. Gellert, G.C.; Dikmen, Z.G.; Wright, W.E.; Gryaznov, S.; Shay, J.W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 2006, 96, 73–81. [CrossRef] [PubMed]
24. Hochreiter, A.E.; Xiao, H.; Goldblatt, E.M.; Gryaznov, S.M.; Miller, K.D.; Badve, S.; Sledge, G.W.; Herbert, B.S. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 2006, 12, 3184–3192. [CrossRef]
25. Herbert, B.; Pitts, A.E.; Baker, S.I.; Hamilton, S.E.; Wright, W.E.; Shay, J.W.; Corey, D.R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA 1999, 96, 14276–14281. [CrossRef] [PubMed]
26. Lin, S.; Wei, J.; Wunderlich, M.; Chou, F.S.; Mulloy, J.C. Immortalization of human ae pre-leukemia cells by htert allows leukemic transformation. Oncotarget 2016, 7, 55939–55950. [CrossRef] [PubMed]
27. Cook, B.D.; Dynek, J.N.; Chang, W.; Shostak, G.; Smith, S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell. Biol. 2002, 22, 332–342. [CrossRef] [PubMed]
28. Riffell, J.L.; Lord, C.J.; Ashworth, A. Tankyrase-targeted therapeutics: Expanding opportunities in the parp family. Nat. Rev. Drug Discov. 2012, 11, 923–936. [CrossRef] [PubMed]
29. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson, S.R.; Paulsen, J.E.; Pedersen, N.M.; Eide, T.J.; Machonova, O.; et al. A novel tankyrase inhibitor decreases canonical wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012, 72, 2822–2832. [CrossRef] [PubMed]
30. Dregalla, R.C.; Zhou, J.; Idate, R.R.; Battaglia, C.L.; Liber, H.L.; Bailey, S.M. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: Suppression of T-SCE and stabilization of DNA-PKcs. Aging 2010, 2, 691–708. [CrossRef] [PubMed]
31. Seimiya, H.; Muramatsu, Y.; Ohishi, T.; Tsuruo, T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005, 7, 25–37. [CrossRef] [PubMed]
32. Fatemi, A.; Safa, M.; Kazemi, A. MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2015, 36, 8425–8437. [CrossRef] [PubMed]
33. Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J.H.; Ohyashiki, K. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: In vitro and in vivo studies in acute leukemia. Oncogene 2006, 25, 5719–5725. [CrossRef] [PubMed]
34. Maestroni, L.; Matmati, S.; Coulon, S. Solving the telomere replication problem. Genes 2017, 8, 55. [CrossRef] [PubMed]
35. Burger, A.M.; Dai, F.; Schultes, C.M.; Reszka, A.P.; Moore, M.J.; Double, J.A.; Neidle, S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005, 65, 1489–1496. [CrossRef] [PubMed]
36. Gunaratnam, M.; Greciano, O.; Martins, C.; Reszka, A.P.; Schultes, C.M.; Morjani, H.; Riou, J.F.; Neidle, S. Mechanism of acridine-based telomerase inhibition and telomere shortening. Biochem. Pharmacol. 2007, 74, 679–689. [CrossRef] [PubMed]
37. Cookson, J.C.; Dai, F.; Smith, V.; Heald, R.A.; Laughton, C.A.; Stevens, M.F.; Burger, A.M. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8Hquino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: Activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol. Pharmacol. 2005, 68, 1551–1558. [PubMed]
38. Salvati, E.; Leonetti, C.; Rizzo, A.; Scarsella, M.; Mottolese, M.; Galati, R.; Sperduti, I.; Stevens, M.F.; D’Incalci, M.; Blasco, M.; et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Investig. 2007, 117, 3236–3247. [CrossRef] [PubMed]
39. Tahara, H.; Shin-Ya, K.; Seimiya, H.; Yamada, H.; Tsuruo, T.; Ide, T. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3’ telomeric overhang in cancer cells. Oncogene 2006, 25, 1955–1966. [CrossRef] [PubMed]
40. Li, Y.; Tergaonkar, V. Noncanonical functions of telomerase: Implications in telomerase-targeted cancer therapies. Cancer Res. 2014, 74, 1639–1644. [CrossRef] [PubMed]
41. Low, K.C.; Tergaonkar, V. Telomerase: Central regulator of all of the hallmarks of cancer. Trends Biochem. Sci. 2013, 38, 426–434. [CrossRef] [PubMed]
42. Indran, I.R.; Hande, M.P.; Pervaiz, S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 2011, 71, 266–276. [CrossRef] [PubMed]
43. Masutomi, K.; Possemato, R.; Wong, J.M.; Currier, J.L.; Tothova, Z.; Manola, J.B.; Ganesan, S.; Lansdorp, P.M.; Collins, K.; Hahn, W.C. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. USA 2005, 102, 8222–8227. [CrossRef] [PubMed]
44. Park, J.I.; Venteicher, A.S.; Hong, J.Y.; Choi, J.; Jun, S.; Shkreli, M.; Chang, W.; Meng, Z.; Cheung, P.; Ji, H.; et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460, 66–72. [CrossRef] [PubMed]
45. Koh, C.M.; Khattar, E.; Leow, S.C.; Liu, C.Y.; Muller, J.; Ang, W.X.; Li, Y.; Franzoso, G.; Li, S.; Guccione, E.; et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J. Clin. Investig. 2015, 125, 2109–2122. [CrossRef] [PubMed]
46. Khattar, E.; Kumar, P.; Liu, C.Y.; Akincilar, S.C.; Raju, A.; Lakshmanan, M.; Maury, J.J.; Qiang, Y.; Li, S.; Tan, E.Y.; et al. Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. J. Clin. Investig. 2016, 126, 4045–4060. [CrossRef] [PubMed]
47. Hahn, W.C.; Stewart, S.A.; Brooks, M.W.; York, S.G.; Eaton, E.; Kurachi, A.; Beijersbergen, R.L.; Knoll, J.H.; Meyerson, M.; Weinberg, R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999, 5, 1164–1170. [PubMed]
48. Li, Y.; Zhou, Q.L.; Sun, W.; Chandrasekharan, P.; Cheng, H.S.; Ying, Z.; Lakshmanan, M.; Raju, A.; Tenen, D.G.; Cheng, S.Y.; et al. Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell biol. 2015, 17, 1327–1338. [CrossRef] [PubMed]
49. Akincilar, S.C.; Khattar, E.; Boon, P.L.; Unal, B.; Fullwood, M.J.; Tergaonkar, V. Long-range chromatin interactions drive mutant tert promoter activation. Cancer Discov. 2016, 6, 1276–1291. [CrossRef] [PubMed]
50. Blackburn, E.H. Telomeres and telomerase: Their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005, 579, 859–862. [CrossRef] [PubMed]
51. Vallarelli, A.F.; Rachakonda, P.S.; Andre, J.; Heidenreich, B.; Riffaud, L.; Bensussan, A.; Kumar, R.; Dumaz, N. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget 2016, 7, 53127–53136. [CrossRef] [PubMed]
52. Queisser, A.; Heeg, S.; Thaler, M.; von Werder, A.; Opitz, O.G. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis. Cancer Genet. 2013, 206, 374–386. [CrossRef] [PubMed]
53. Kyo, S.; Takakura, M.; Fujiwara, T.; Inoue, M. Understanding and exploiting htert promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99, 1528–1538. [CrossRef] [PubMed]
54. Li, G.Z.; Eller, M.S.; Firoozabadi, R.; Gilchrest, B.A. Evidence that exposure of the telomere 3’ overhang sequence induces senescence. Proc. Natl. Acad. Sci. USA 2003, 100, 527–531. [CrossRef] [PubMed]
55. Saretzki, G.; Sitte, N.; Merkel, U.; Wurm, R.E.; von Zglinicki, T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene 1999, 18, 5148–5158. [CrossRef] [PubMed]
56. Gnanasekar, M.; Thirugnanam, S.; Zheng, G.; Chen, A.; Ramaswamy, K. T-oligo induces apoptosis in advanced prostate cancer cells. Oligonucleotides 2009, 19, 287–292. [CrossRef] [PubMed]
57. Rankin, A.M.; Forman, L.; Sarkar, S.; Faller, D.V. Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells. Nucleic Acid Ther. 2013, 23, 311–321. [CrossRef] [PubMed]
58. Bates, P.J.; Laber, D.A.; Miller, D.M.; Thomas, S.D.; Trent, J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009, 86, 151–164. [CrossRef] [PubMed]
59. Weng, D.; Cunin, M.C.; Song, B.; Price, B.D.; Eller, M.S.; Gilchrest, B.A.; Calderwood, S.K.; Gong, J. Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. Breast Cancer Res. 2010, 12, R71. [CrossRef] [PubMed]
60. Longe, H.O.; Romesser, P.B.; Rankin, A.M.; Faller, D.V.; Eller, M.S.; Gilchrest, B.A.; Denis, G.V. Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: Mechanism and therapeutic potential. Int. J. Cancer 2009, 124, 473–482. [CrossRef] [PubMed]
61. Wojdyla, L.; Stone, A.L.; Sethakorn, N.; Uppada, S.B.; Devito, J.T.; Bissonnette, M.; Puri, N. T-oligo as an anticancer agent in colorectal cancer. Biochem. Biophys. Res. Commun. 2014, 446, 596–601. [CrossRef] [PubMed]
62. Sarkar, S.; Faller, D.V. Telomere-homologous g-rich oligonucleotides sensitize human ovarian cancer cells to trail-induced growth inhibition and apoptosis. Nucleic Acid Ther. 2013, 23, 167–174. [CrossRef] [PubMed]
63. Puri, N.; Eller, M.S.; Byers, H.R.; Dykstra, S.; Kubera, J.; Gilchrest, B.A. Telomere-based DNA damage responses: A new approach to melanoma. FASEB J. 2004, 18, 1373–1381. [CrossRef] [PubMed]
64. Puri, N.; Pitman, R.T.; Mulnix, R.E.; Erickson, T.; Iness, A.N.; Vitali, C.; Zhao, Y.; Salgia, R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014, 343, 14–23. [CrossRef] [PubMed]
65. Coleman, C.; Levine, D.; Kishore, R.; Qin, G.; Thorne, T.; Lambers, E.; Sasi, S.P.; Yaar, M.; Gilchrest, B.A.; Goukassian, D.A. Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides. J. Oncol. 2010, 2010, 928628. [CrossRef] [PubMed]
66. Uppada, S.B.; Erickson, T.; Wojdyla, L.; Moravec, D.N.; Song, Z.; Cheng, J.; Puri, N. Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. Int. J. Nanomed. 2014, 9, 43–53.
67. Yaar, M.; Eller, M.S.; Panova, I.; Kubera, J.; Wee, L.H.; Cowan, K.H.; Gilchrest, B.A. Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res. 2007, 9, R13. [CrossRef] [PubMed]
68. Rankin, A.M.; Faller, D.V.; Spanjaard, R.A. Telomerase inhibitors and ‘T-oligo’ as cancer therapeutics: Contrasting molecular mechanisms of cytotoxicity. Anti-Cancer Drugs 2008, 19, 329–338. [CrossRef] [PubMed]
69. Karlseder, J.; Smogorzewska, A.; de Lange, T. Senescence induced by altered telomere state, not telomere loss. Science 2002, 295, 2446–2449. [CrossRef] [PubMed]
70. Van Steensel, B.; Smogorzewska, A.; de Lange, T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998, 92, 401–413. [CrossRef]
71. Pitman, R.T.; Wojdyla, L.; Puri, N. Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget 2013, 4, 761–771. [CrossRef] [PubMed]
72. Eller, M.S.; Li, G.Z.; Firoozabadi, R.; Puri, N.; Gilchrest, B.A. Induction of a p95/Nbs1-mediated s phase checkpoint by telomere 3’ overhang specific DNA. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2003, 17, 152–162. [CrossRef] [PubMed]
73. Page, T.J.; Mata, J.E.; Bridge, J.A.; Siebler, J.C.; Neff, J.R.; Iversen, P.L. The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells. Exp. Cell Res. 1999, 252, 41–49. [CrossRef] [PubMed]
74. Calado, R.T.; Dumitriu, B. Telomere dynamics in mice and humans. Semin. Hematol. 2013, 50, 165–174. [CrossRef] [PubMed]
75. Gomes, N.M.; Ryder, O.A.; Houck, M.L.; Charter, S.J.; Walker, W.; Forsyth, N.R.; Austad, S.N.; Venditti, C.; Pagel, M.; Shay, J.W.; et al. Comparative biology of mammalian telomeres: Hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 2011, 10, 761–768. [CrossRef] [PubMed]
76. Kim, S.H.; Parrinello, S.; Kim, J.; Campisi, J. Mus musculus and mus spretus homologues of the human telomere-associated protein TIN2. Genomics 2003, 81, 422–432. [CrossRef]
77. Broccoli, D.; Chong, L.; Oelmann, S.; Fernald, A.A.; Marziliano, N.; van Steensel, B.; Kipling, D.; Le Beau, M.M.; de Lange, T. Comparison of the human and mouse genes encoding the telomeric protein, TRF1: Chromosomal localization, expression and conserved protein domains. Hum. Mol. Genet. 1997, 6, 69–76. [CrossRef] [PubMed]
78. Palm, W.; Hockemeyer, D.; Kibe, T.; de Lange, T. Functional dissection of human and mouse POT1 proteins. Mol. Cell. Biol. 2009, 29, 471–482. [CrossRef] [PubMed]
79. Tian, X.; Dai, S.; Sun, J.; Jiang, S.; Sui, C.; Meng, F.; Li, Y.; Fu, L.; Jiang, T.; Wang, Y.; et al. Bufalin induces mitochondria-dependent apoptosis in pancreatic and oral cancer cells by downregulating hTERT expression via activation of the JNK/p38 pathway. Evide-Based Complement. Altern. Med. 2015, 2015, 546210. [CrossRef] [PubMed]
80. Eller, M.S.; Liao, X.; Liu, S.; Hanna, K.; Backvall, H.; Opresko, P.L.; Bohr, V.A.; Gilchrest, B.A. A role for WRN in telomere-based DNA damage responses. Proc. Natl. Acad. Sci. USA 2006, 103, 15073–15078. [CrossRef] [PubMed]
81. Lu, H.; Wang, J.; Bai, Y.; Lang, J.W.; Liu, S.; Lin, Y.; Cheng, J. Ionic polypeptides with unusual helical stability. Nat. Commun. 2011, 2, 206. [CrossRef] [PubMed]
82. Yen, J.; Zhang, Y.; Gabrielson, N.P.; Yin, L.; Guan, L.; Chaudhury, I.; Lu, H.; Wang, F.; Cheng, J. Cationic, helical polypeptide-based gene delivery for IMR-90 fibroblasts and human embryonic stem cells. Biomater. Sci. 2013, 1, 719–727. [CrossRef] [PubMed]
83. Wan, C.; Allen, T.M.; Cullis, P.R. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 2014, 4, 74–83. [CrossRef] [PubMed]
84. Wissing, S.A.; Kayser, O.; Muller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56, 1257–1272. [CrossRef] [PubMed]
85. Rajanna, S.; Rastogi, I.; Wojdyla, L.; Furo, H.; Kulesza, A.; Lin, L.; Sheu, B.; Frakes, M.; Ivanovich, M.; Puri, N. Current molecularly targeting therapies in NSCLC and melanoma. Anti-Cancer Agents Med. Chem. 2015, 15, 856–868. [CrossRef]